Harpoon Therapeutics (HARP) News Today → **Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! (From Huge Alerts) (Ad) Free HARP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16, 2024 | msn.comAmgen Drug Wins US Approval for Type of Advanced Lung CancerMay 14, 2024 | forbes.comIs Johnson & Johnson Stock A Better Pick Over Merck?May 14, 2024 | markets.businessinsider.comViracta Therapeutics Appoints Faerm As CFOMay 8, 2024 | msn.comMerck and other pharma giants are bracing for competition to their blockbuster drugs. Here's how.April 25, 2024 | msn.comMerck raises 2024 profit forecast on surging sales of cancer drug KeytrudaMarch 16, 2024 | finance.yahoo.comHARP Apr 2024 20.000 putMarch 16, 2024 | finance.yahoo.comHARP Sep 2024 20.000 putMarch 13, 2024 | marketbeat.comShort Interest in Harpoon Therapeutics, Inc. (NASDAQ:HARP) Declines By 53.6%Harpoon Therapeutics, Inc. (NASDAQ:HARP - Get Free Report) saw a significant drop in short interest in February. As of February 29th, there was short interest totalling 538,400 shares, a drop of 53.6% from the February 14th total of 1,160,000 shares. Approximately 4.3% of the company's shares are short sold. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is currently 0.5 days.March 13, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Merck & Company (MRK)March 12, 2024 | msn.comMerck completes acquisition of Harpoon TherapeuticsMarch 12, 2024 | insidertrades.comHarpoon Therapeutics, Inc. (NASDAQ:HARP) Major Shareholder Buys $492,135,715.00 in StockMarch 11, 2024 | marketbeat.comMerck & Co., Inc. Acquires 21,397,205 Shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP) StockHarpoon Therapeutics, Inc. (NASDAQ:HARP - Get Free Report) major shareholder Merck & Co., Inc. bought 21,397,205 shares of the firm's stock in a transaction that occurred on Monday, March 11th. The shares were acquired at an average price of $23.00 per share, with a total value of $492,135,715.00. Following the purchase, the insider now owns 1,000 shares in the company, valued at $23,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.March 11, 2024 | marketbeat.comHarpoon Therapeutics, Inc. (NASDAQ:HARP) Position Lessened by Kennedy Capital Management LLCKennedy Capital Management LLC lowered its position in Harpoon Therapeutics, Inc. (NASDAQ:HARP - Free Report) by 90.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 52,987 shares of the company's stock after selling 476,9March 11, 2024 | marketbeat.comTrading was temporarily halted for "HARP" at 07:03 PM with a stated reason of "News pending."March 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), Brainsway (BWAY) and Wave Life Sciences (WVE)March 6, 2024 | msn.comHarpoon Therapeutics ticks higher amid Nasdaq delisting notice for sale to MerckMarch 6, 2024 | marketbeat.comAcadian Asset Management LLC Sells 69,040 Shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP)Acadian Asset Management LLC decreased its holdings in Harpoon Therapeutics, Inc. (NASDAQ:HARP - Free Report) by 90.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,670 shares of the company's stock after selling 69,040March 1, 2024 | marketbeat.comHarpoon Therapeutics, Inc. (NASDAQ:HARP) Shares Sold by MPM Bioimpact LLCMPM Bioimpact LLC lowered its position in shares of Harpoon Therapeutics, Inc. (NASDAQ:HARP - Free Report) by 90.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 319,670 shares of the company's stock after selling 2,8February 27, 2024 | msn.comCitigroup Downgrades Harpoon Therapeutics (HARP)February 26, 2024 | markets.businessinsider.comAnalyst Scoreboard: 4 Ratings For Harpoon TherapeuticsFebruary 26, 2024 | marketbeat.comHarpoon Therapeutics (NASDAQ:HARP) Rating Reiterated by CitigroupCitigroup restated a "neutral" rating and issued a $23.00 price target (up from $13.00) on shares of Harpoon Therapeutics in a research note on Monday.February 24, 2024 | realmoney.thestreet.comHarpoon Therapeutics just downgraded at Citi, here's whyFebruary 23, 2024 | usnews.comFate of US Aid to Ukraine Package Discussed on Taiwan Trip, Lawmakers SayFebruary 23, 2024 | msn.comMerck wins EU backing for Keytruda use in resectable lung cancerFebruary 23, 2024 | finance.yahoo.comHARPOON THERAPEUTICS (5HTA.BE)February 23, 2024 | finance.yahoo.comHarpoon Therapeutics Inc. (5HTA.SG)February 22, 2024 | benzinga.comStock (HARP), Short Interest ReportFebruary 17, 2024 | marketbeat.comHarpoon Therapeutics, Inc. (NASDAQ:HARP) Short Interest Up 15.2% in JanuaryHarpoon Therapeutics, Inc. (NASDAQ:HARP - Get Free Report) was the recipient of a large growth in short interest in January. As of January 31st, there was short interest totalling 547,700 shares, a growth of 15.2% from the January 15th total of 475,400 shares. Currently, 5.5% of the shares of the stock are short sold. Based on an average trading volume of 673,500 shares, the days-to-cover ratio is presently 0.8 days.February 13, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), 4D Molecular Therapeutics (FDMT)February 1, 2024 | msn.comMerck Hasn't Even Closed Its Last Buyout, But It's Already Hunting For The Next DealJanuary 30, 2024 | finance.yahoo.comWhile private equity firms own 20% of Harpoon Therapeutics, Inc. (NASDAQ:HARP), retail investors are its largest shareholders with 36% ownershipJanuary 19, 2024 | finanznachrichten.deArix Bioscience PLC: Financial update on Harpoon Therapeutics acquisition by Merck (MSD)January 18, 2024 | marketbeat.comMerck, the Dow's hottest stock, gets set to report Q4 financials (HARP)Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks.January 16, 2024 | markets.businessinsider.comPeeling Back The Layers: Exploring Harpoon Therapeutics Through Analyst InsightsJanuary 16, 2024 | marketbeat.comHarpoon Therapeutics (NASDAQ:HARP) Given "Market Perform" Rating at TD CowenTD Cowen reiterated a "market perform" rating on shares of Harpoon Therapeutics in a research note on Tuesday.January 11, 2024 | marketbeat.comEquities Analysts Issue Forecasts for Harpoon Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:HARP)Harpoon Therapeutics, Inc. (NASDAQ:HARP - Free Report) - Equities research analysts at HC Wainwright issued their FY2028 earnings estimates for shares of Harpoon Therapeutics in a research report issued on Monday, January 8th. HC Wainwright analyst S. Ramakanth forecasts that the company will earJanuary 11, 2024 | baystreet.caMerck Stock Gains After Snatching Harpoon TherapeuticsJanuary 10, 2024 | marketbeat.comHarpoon Therapeutics (NASDAQ:HARP) Downgraded by Leerink Partnrs to "Market Perform"Leerink Partnrs downgraded Harpoon Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Monday.January 9, 2024 | msn.comMerck Buys Harpoon Therapeutics To Expand Its Oncology PortfolioJanuary 9, 2024 | finance.yahoo.comMerck (MRK) to Strengthen Cancer Pipeline With Harpoon BuyoutJanuary 8, 2024 | marketbeat.comHarpoon Therapeutics (NASDAQ:HARP) Given Neutral Rating at HC WainwrightHC Wainwright restated a "neutral" rating and issued a $23.00 target price (up previously from $12.00) on shares of Harpoon Therapeutics in a report on Monday.January 8, 2024 | marketbeat.comBoeing, Alaska Air Group fall; Harpoon Therapeutics, Axonics rise, Monday, 1/8/2024Stocks that are trading heavily or have substantial price changes on Monday: Boeing, Alaska Air Group fall; Harpoon Therapeutics, Axonics riseJanuary 8, 2024 | investorplace.comWhy Is Harpoon Therapeutics (HARP) Stock Up 111% Today?January 8, 2024 | markets.businessinsider.comMerck In Talks To Acquire Harpoon Therapeutics: ReportsJanuary 8, 2024 | marketwatch.comHarpoon Therapeutics Shares Take Flight Premarket on Report of Merck Deal TalksJanuary 8, 2024 | markets.businessinsider.comHarpoon Therapeutics, Heron Therapeutics And Other Big Stocks Moving Higher In Monday's Pre-Market SessionJanuary 8, 2024 | benzinga.comWhy Is Cancer Focused Harpoon Therapeutics Stock Shooting Higher Today?January 8, 2024 | msn.comBiggest stock movers today: Boeing, Harpoon Therapeutics, and moreJanuary 8, 2024 | finance.yahoo.comMerck to Acquire Harpoon Therapeutics, Further Diversifying Oncology PipelineJanuary 8, 2024 | ca.finance.yahoo.comMerck to buy Harpoon Therapeutics for $680 million Get Harpoon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HARP and its competitors with MarketBeat's FREE daily newsletter. Email Address Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide HARP Media Mentions By Week HARP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HARP News Sentiment▼0.530.42▲Average Medical News Sentiment HARP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HARP Articles This Week▼32▲HARP Articles Average Week Get Harpoon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HARP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TERN News LFMD News MODV News ACB News ANRO News ANIK News KRRO News CERS News ORGO News SLDB News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HARP) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldUrgent Nvidia WarningAltimetryThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harpoon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
